129 related articles for article (PubMed ID: 34763589)
21. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
22. Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor.
Lamberti G; Faggiano A; Brighi N; Tafuto S; Ibrahim T; Brizzi MP; Pusceddu S; Albertelli M; Massironi S; Panzuto F; Badalamenti G; Riccardi F; Butturini G; Gelsomino F; De Divitiis C; Modica R; Bongiovanni A; La Salvia A; Torchio M; Colao A; Ferone D; Campana D
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31545377
[TBL] [Abstract][Full Text] [Related]
23. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
[TBL] [Abstract][Full Text] [Related]
24. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of
Bongiovanni A; Recine F; Riva N; Foca F; Liverani C; Mercatali L; Nicolini S; Pieri F; Amadori D; Ibrahim T
Clin Lung Cancer; 2017 Jul; 18(4):415-420. PubMed ID: 27956089
[TBL] [Abstract][Full Text] [Related]
25. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
[TBL] [Abstract][Full Text] [Related]
26. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
[TBL] [Abstract][Full Text] [Related]
27. Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.
Khasraw M; Townsend A; Price T; Hart J; Bell D; Pavlakis N
Intern Med J; 2010 Jun; 40(6):453-8. PubMed ID: 20636828
[TBL] [Abstract][Full Text] [Related]
28. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.
Joish VN; Frech F; Lapuerta P
Clin Ther; 2017 Dec; 39(12):2338-2344. PubMed ID: 29175096
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.
Joish VN; Frech F; Lapuerta P
J Med Econ; 2018 Feb; 21(2):182-188. PubMed ID: 28959913
[TBL] [Abstract][Full Text] [Related]
30. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
[TBL] [Abstract][Full Text] [Related]
31. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
32. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
33. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
[TBL] [Abstract][Full Text] [Related]
35. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
[TBL] [Abstract][Full Text] [Related]
36. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
Krug S; Mordhorst JP; Moser F; Theuerkorn K; Ruffert C; Egidi M; Rinke A; Gress TM; Michl P
PLoS One; 2019; 14(6):e0218953. PubMed ID: 31237925
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
Barnes JI; Lin JK; Gupta D; Owens DK; Goldhaber-Fiebert JD; Kunz PL
J Natl Compr Canc Netw; 2020 Sep; 18(9):1200-1209. PubMed ID: 32886901
[TBL] [Abstract][Full Text] [Related]
38. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.
Carmona-Bayonas A; Jiménez-Fonseca P; Lamarca Á; Barriuso J; Castaño Á; Benavent M; Alonso V; Riesco-Martínez MDC; Alonso-Gordoa T; Custodio A; Sánchez Cánovas M; Hernando Cubero J; López C; Lacasta A; Fernández Montes A; Marazuela M; Crespo G; Escudero P; Diaz JÁ; Feliciangeli E; Gallego J; Llanos M; Segura Á; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle JW; García-Carbonero R
J Clin Oncol; 2019 Oct; 37(28):2571-2580. PubMed ID: 31390276
[TBL] [Abstract][Full Text] [Related]
39. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
40. Neuroendocrine tumours - Medical therapy: Biological.
Rinke A; Krug S
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):79-91. PubMed ID: 26971845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
